In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01651-25 ↗Kurz gefasst
Fallbericht in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Daniel C Bailey und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virgini…. Hauptthemen laut MEDLINE: Serratia marcescens, beta-Lactamase Inhibitors, Serratia Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Klebsiella pneumoniae carbapenemases (KPCs) are a family of serine β-lactamases that confer broad antibiotic resistance by hydrolyzing virtually all β-lactam (BL) agents. Contemporary β-lactamase inhibitors (BLIs) such as avibactam were developed to neutralize the activity of KPCs and other clinically important carbapenemases. Ceftazidime-avibactam (CZA), a BL/BLI combination in which the cephalosporin ceftazidime is protected from KPC-mediated hydrolysis, demonstrated improved outcomes in early clinical use. However, CZA-resistant isolates soon emerged. Herein, we describe a challenging clinical case in which high-level resistance to CZA evolved during therapy for a complicated infection caused by carbapenem-resistant Serratia marcescens harboring bla KPC-2 . Whole-genome sequencing, analysis of antibiotic resistance genes, and phenotypic susceptibility assays of serial S. marcescens isolates revealed that resistance arose via a 45-nucleotide in-frame duplication within bla KPC-2 , yielding KPC variant 44 ( bla KPC-44 ). Notably, the evolution of bla KPC-44 not only conferred resistance to CZA but also marked cross-resistance to meropenem-vaborbactam and imipenem-relebactam while remaining susceptible to cefiderocol. To our knowledge, this report represents the first description of bla KPC-44 emerging outside of K. pneumoniae and among the few documenting a CZA-resistance-conferring KPC variant emerging in a non -K . pneumoniae Enterobacterales species. Ultimately, the evolved strain persisted despite therapy throughout a fatal clinical course, underscoring the potential for CZA selective pressure to drive treatment-emergent resistance to multiple contemporary BL/BLI agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
- Clinical Microbiology Laboratory, University of Virginia Health System, Charlottesville, Virginia, USA.
- Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
ORCID-Profile: Daniel C Bailey, Salvador Castañeda-Barba, Puthayalai Treerat, Matthew A Crawford, Molly A Hughes, Amy J Mathers
Förderung
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Bailey, D. C., Castañeda-Barba, S., Barry, K. E., Treerat, P., Crawford, M. A., Hughes, M. A., & Mathers, A. J. (2026). In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01651-25
Vancouver
Bailey DC, Castañeda-Barba S, Barry KE, Treerat P, Crawford MA, Hughes MA, et al. In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01651-25
BibTeX
@article{Bailey2026,
author = {Bailey, Daniel C and Castañeda-Barba, Salvador and Barry, Katie E and Treerat, Puthayalai and Crawford, Matthew A and Hughes, Molly A and Mathers, Amy J},
title = {In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01651-25}
}
EUVIMED